Article
Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib).
Molecular cancer - 21 Jun 2012
Fei Fei, Lim Min, Schmidhuber Sabine, Moll Jürgen, Groffen John, Heisterkamp Nora
Abstract excerpt
BACKGROUND: Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemias (Ph-positive ALL) with clinically approved inhibitors of the Bcr/Abl tyrosine kinase frequently results in the emergence of a leukemic clone carrying the T315I mutation in Bcr/Abl, which confers resistance to these drugs. PHA-739358, an Aurora kinase inhibitor, was reported to inhibit the Bcr/Abl T315I mutant in CML cells but...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.